Table 3 Review of the main clinical trials performed in first line metastatic colorectal cancer

Tournigand C et al. [9]

FOLFIRI

NR

56

56

8.5

21.5

J Clin Oncol 2004; 22(2):229–37.

Colluci G et al. [34]

FOLFIRI

50

56

31

7

14

J Clin Oncol 2005; 23:4866–4875.

Labiancha R et al. [35]

FOLFIRI

NR

NR

42

6

18

Annals of Oncology 2011; 22:1236–1242.

Koopman M (CAIRO study) [36]

FOLFOX or FOLFIRI

23

NR

41

7,8

17.4

Lancet 2007; 370:135–42.

Ducreux M (FFCD2000-05) [37]

FOLFOX

NR

52

58

7.6

16.2

Lancet Oncol 2011; 12:1032–44.

Chibaudel B (OPTIMOX2 study) [25]

FOLFOX7

NR

42

59.6

8,6

23.8

J Clin Oncol 2009; 27:5727–5733.

Maintenance arm

Maughan TS (COIN study arm 1) [38]

FOLFOX

21

35

57

8,6

17.9

Lancet 2011; 377(9783):2103–2114.

Hurwitz H et al. [13]

IFL + Bev

NR

37

44.8

10.6

20.3

N Engl J Med 2004; 350:2335–42.

Fuchs CS (BICC study) [23]

Folfiri-bev

NR

NR

57.9

11.2

28

J Clin Oncol 2007; 25:4779–4786.

SALTZ LB (NO16966) [39]

FOLFOX + bev

NR

43

9.4

21.3

J Clin Oncol. 2008; 26(12):2013–9.

Schmoll HJ (Horizon study) [40]

FOLFOX + bev

22

45

47

10.3

22.3

J Clin Oncol 2012; 30:3588–3595.

Van Cutsem(Crystal study) [41]

FOLFIRI cetux

21,5

NR

57,2

9.9

23.5

J Clin Oncol 2011; 29:2011–2019.

Kras wt only

Maughan TS (COIN study arm 2) [38]

FOLFOX cetux

24

37

64

8.6

17

Lancet. 2011; 377(9783):2103–2114.

Kras wt only

Douillard JY (Prime study) [42]

FOLFOX pamitumumab

18

21

55

9.6

23.9

J Clin Oncol 2010; 28:4697–4705.

Kras wt only

Bokemeyer (OPUS study) [43]

FOLFOX + cetux

30

44

58

8.3

22.8

Annals of Oncology 2011; 22:1535–1546.

Kras wt only

Masi G [44]

FOLFOXIRI

34

55

60

9.8

23.4

J Natl Cancer Inst 2011;103:21–30.

Masi G [30]

FOLFOXIRI beva

53

58

77

13.1

30.9

Lancet Oncol 2010; 11:845–52.